Plain-English translation of NCT07114601 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Neoplasms research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new cancer treatment called , which is a type of targeted radiation therapy designed to find and attack cancer cells that have a specific protein called GRPR. Researchers want to understand how safe this medication is, how well people tolerate it, and whether it helps shrink tumors. The study includes people with several types of advanced cancer, including breast, colorectal, prostate, endometrial, and stomach cancers.
Many people with advanced cancer need new treatment options, especially when standard therapies stop working. This medication is designed to target cancer cells more precisely by finding a specific protein on the tumor surface, which may help attack cancer while reducing harm to healthy tissue.
You likely qualify if…
You likely don't qualify if…
You would receive the new medication as an intravenous infusion (through an IV) at clinic visits, either alone or combined with your regular cancer treatment, depending on which study group you're in. You'll have regular check-ups, blood tests, and imaging scans to monitor how you're responding and check for any side effects. Your participation could last up to 36 weeks or until your cancer progresses, with frequent outpatient visits to the research clinic.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States